In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI – Research Report), with a price target of $22.00. The company's shares closed last Thursday at $7.46, close to its 52-week low of $6.67. According to TipRanks.com, Belanger is a 1-star analyst with an average return of -0.3% and a 37.3% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical. Currently, the analyst consensus on Aerie Pharma is a Moderate Buy with an average price target of $21.00.
https://www.tipranks.com/news/blurbs/needham-thinks-aerie-pharmas-stock-is-going-to-recover-5?utm_source=advfn.com&utm_medium=referral